Publications by authors named "P Faurie"
Article Synopsis
- - The study investigates the management of adolescent and young adult (AYA) patients aged 13-25 with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in the Rhône-Alpes region from 2000 to 2005, comparing treatment approaches in adult versus pediatric units.
- - Out of 278 patients, the majority were treated in adult units, where they experienced longer wait times before treatment compared to those in pediatric units; overall survival rates were high, with 96% for HL and 90% for NHL.
- - The study highlights significant differences in chemotherapy and radiotherapy practices between adult and pediatric management, indicates that adherence to clinical practice guidelines was low (56%), and suggests that a more uniform
Purpose: Plasmablastic lymphoma (PBL) is a rare variant of diffuse large B cell lymphomas (DLBCL) clinically characterized by a poorer prognostic. Few clinical and imaging data are available and derived from pooled case reports and small series. The aim of the study was to evaluate the FDG avidity at baseline and the utility of 18-Fluorodeoxyglucose (FDG) positron-emission-tomography/computed-tomography (PET/CT) for staging and response assessment.
View Article and Find Full Text PDFIntroduction: Acquired hemophilia A is a factor VIII deficiency related to anti-factor VIII immunoglobulins. We are reporting the case of a patient with acquired hemophilia A related to chronic myelomonocytic leukemia.
Case Report: A 74-years old woman had a spontaneous calf hematoma with compression syndrome.
Primary CNS lymphoma (PCNSL) is chemosensitive to high-dose methotrexate-based chemotherapy. However, responses in the elderly are short-lasting and outcome is poor. Given that radiotherapy and intensive chemotherapy expose elderly to severe toxicities, alternative consolidation approaches need to be evaluated.
View Article and Find Full Text PDFBackground: Plasmablastic lymphoma (PBL), initially described in 1997 in the oral cavity of HIV positive patients, is now recognized as a distinct aggressive and rare entity of diffuse large B-cells lymphoma by the World Health Organization (WHO) classification. Since the original description, others cases have been reported. However, these are largely derived from case reports or small series limiting any definitive conclusions on clinical characteristics and outcome.
View Article and Find Full Text PDF